Join the Lymphoma group to help and get support from people like you.
Lymphoma News
Related terms: Cancer, Lymphoma
Obesity at Pediatric Cancer Diagnosis Linked to Inferior Survival
MONDAY, Jan. 13, 2025 – Obesity at cancer diagnosis is associated with inferior survival among children aged 2 to 18 years, according to a study published online Jan. 13 in Cancer. Samuel Sassine,...
Position Statement Developed for Managing Blood Cancers in Pregnancy
WEDNESDAY, Jan. 8, 2025 – In a new position statement published online Jan. 3 in The Lancet Haematology, guidelines are presented for the management of acute leukemia and aggressive lymphomas in...
Keto Diet Supplement Could Boost a Cancer Treatment's Effectiveness
MONDAY, Dec. 9, 2024 (HealthDay News) – A component of the keto diet appears to boost the powers of immunotherapy in treating cancer, a new study finds. Beta-hydroxybutyrate (BHB), an acid produced b...
ASH: Auto-HCT Not Beneficial for Mantle Cell Lymphoma With Undetectable Residual Disease
FRIDAY, Dec. 6, 2024 – Autologous hematopoietic cell transplant (auto-HCT) is not beneficial for patients with mantle cell lymphoma (MCL) in first complete remission (CR) with undetectable minimal...
Late-Stage Lymphoma Less Likely for Young With Continuous Medicaid Coverage
WEDNESDAY, Nov. 13, 2024 – Children and adolescents and young adults (AYAs) diagnosed with lymphoma and insured by Medicaid who maintain Medicaid coverage before diagnosis are less likely to have...
Protracted Radiation Exposure Linked to Hematologic Cancer Mortality
THURSDAY, Oct. 24, 2024 – Protracted low-dose exposure to ionizing radiation among radiation-monitored workers is associated with mortality due to some hematologic malignancies, according to a study...
Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
WEDNESDAY, Oct. 16, 2024 – For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields longer progression-free survival (PFS) than...
Liso-Cel Has Favorable Safety Profile for Outpatients With Large B-Cell Lymphoma
MONDAY, Oct. 7, 2024 – For patients with relapsed/refractory large B-cell lymphoma (LBCL), the autologous, CD19-directed, 4-1BB chimeric antigen receptor T-cell product, lisocabtagene maraleucel...
Black, White Cancer Patients Now Benefit Equally From Cord Blood Therapy
TUESDAY, Oct. 1, 2024 – Blood cancer patients of all races who receive cord blood transplants are now living longer. The finding, reported by a team led by oncologist Dr. Karen Ballen, of UVA...
Outpatient CAR-T Cancer Therapy Can Be Safe, Effective
TUESDAY, Oct. 1, 2024 – Patients with fast-spreading blood cancer respond well to outpatient treatment with CAR-T therapy, the largest study examining its use in a community setting has found. CAR-T...
Blood Cancers: What You Need to Know
SATURDAY, Sept. 28, 2024 – Blood cancer is not a diagnosis anyone wants to receive, but understanding the different types of this disease and how best to catch them early is essential, one expert...
Non-Hispanic Black Patients Have Disparities in HCT Use for Hematologic Cancers
THURSDAY, Sept. 26, 2024 – Non-Hispanic Black patients in the United States appear to have persistent disparities in terms of hematopoietic cell transplantation (HCT) for various hematologic...
Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard of Care
THURSDAY, Sept. 12, 2024 – The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen receptor (CAR) T-cell therapy, according to a study...
Toxicities Rare After Two Weeks of CAR T-Cell Therapy Infusion
TUESDAY, July 30, 2024 – New-onset cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are rare beyond two weeks following infusion of CD19-directed...
Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma
WEDNESDAY, June 26, 2024 – Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL),...
Further information
Related condition support groups
Non-Hodgkin's Lymphoma, Blood Disorders